Targets › PHD1
1 program from 1 company in 1 trial: 1 Phase 1; Hematology; next expected readout Dec 2027.
Open in Phaseline: the race on PHD1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Ascentage Pharma Group | APG-5918 HIF-PHD inhibitor | PHD1, PHD2, PHD3 | Phase 1 | Anemia | Dec 2027 |
Anemia (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.